Abbott Laboratories (ABT)
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Stifel Has Big Second-Half Stock Market Concerns: 5 Defensive Value Dividend Stocks Buys
If there is one voice on Wall Street that we always listen to, it is Stifel's Barry Bannister, and with good reason.
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Abbott Reveals Positive Outcome From REFLECT Studies, Stock Climbs
Per REFLECT studies, ABT's Libre technology is the first CGM linked to fewer hospitalizations for heart complications in people with diabetes.
Abbott (ABT) Up 1.8% Since Last Earnings Report: Can It Continue?
Abbott (ABT) reported earnings 30 days ago. What's next for the stock?
Abbott Outpaces Peers Defying Tariff Woes: Is ABT Stock a Smart Buy?
Despite trade policy challenges, Abbott's global footprint and 90 manufacturing sites offer flexibility to manage regional risks and reroute supply chains.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
MedTechs Adjust 2025 Outlook Amid Tariffs: What Investors Need to Know
Most of the MedTech players have adjusted their 2025 forecasts in response to rising tariff pressure.
Tariffs Cast a Shadow on Abbott's 2025 View: Time to Sell ABT Stock?
With certain devices being imported into the United States from overseas, tariff-induced cost pressure is set to rise for Abbott from the third quarter of 2025.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Abbott Labs' Rally Is Well Deserved - Fade The Rally For Now
ABT continues to offer a compelling high-growth investment thesis, driven by the GLP-1 tailwinds on its Continuous Glucose Monitoring and adult nutrition offerings. This is significantly aided by the management's ability to reiterate its ambitious FY2025 guidance, despite the supposed hundreds of millions in tariff impact. Combined with the richer Free Cash Flow generation, healthier balance sheet, and high single-digits dividend per share growth, we believe that ABT remains well positioned to outperform ahead.
Abbott Q1: Flexible Supply Chain And Strong Growth In Medical Devices
I reiterate a "Strong Buy" rating on Abbott Laboratories, driven by strong growth in medical device and pharma markets, with a fair value of $160 per share. Abbott reported 6.9% organic revenue growth and 8.3% growth excluding COVID testing, driven by 12.6% growth in medical devices and 7.8% in pharma. Abbott's diversified global supply chain and 25 new products in the pipeline position it well to navigate tariff impacts and drive future growth.
